Title: Dexmedetomidine as an Adjunctive Sedative in Patients Undergoing Endoscopic Submucosal Dissection: A Systematic Review and Meta-Analysis

Hazem Abosheaishaa, MD, MSc¹, Abdallfatah Abdallfatah, MS^{2*}, Abdelmalek Abdelghany, MS², Arshia Sethi MD³, Abdellatif Ismail, MD⁴, Doha Mohamed, MS², Moataz Aboeldahb, MD⁵, Omar Abdelhalim, MD³, Islam Mohamed, MD⁶, Ahmed Y. Azzam, MD, MEng⁷, Muhammed Amir Essibayi, MD^{7, 8}, David J. Altschul^{7, 8}, Mahmoud Nassar, MD⁹, Mohammad Bilal, MD¹⁰

- 1- Department of Internal Medicine, Icahn School of Medicine at Mount Sinai / NYC Health + Hospitals, Queens, New York, USA.
- 2- Faculty of Medicine, October 6 University, 6th of October City, Giza, Egypt.
- 3- Icahn School of Medicine at Mount Sinai / NYC Health + Hospitals, Queens, New York, USA.
- 4- University of Maryland Medical Center Midtown Campus, 827 Linden Ave, Baltimore, MD 21201, USA.
- 5- Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, 200 First St. SW Rochester, MN 55905, USA.
- 6- Division of Gastroenterology and Hepatology, Department of Medicine, University of Missouri School of Medicine, Room CE405, 1 Hospital Dr, Columbia, MO 65201, USA.
- 7- Montefiore-Einstein Cerebrovascular Research Lab, Albert Einstein College of Medicine, Bronx, NY, USA.
- 8- Department of Neurological Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
- 9- Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, New York, USA.
- 10-Division of Gastroenterology and Hepatology, Department of Medicine, Minneapolis Veterans Affairs Medical Center, Minneapolis, MN 55417, USA.

Corresponding Author: *

Abdallfatah Abdallfatah, MS,

Faculty of Medicine,

October 6 University,

6th of October City, Giza, Egypt.

Email Address: <u>Abdallfatahofficial@gmail.com</u>

It is made available under a CC-BY-ND 4.0 International license .

Abstract:

Introduction: Endoscopic submucosal dissection (ESD) allows for curative en-bloc resection of dysplastic gastrointestinal (GI) tract lesions. However, it is associated with postoperative adverse events (AEs) such as pain, bleeding, and perforation. Dexmedetomidine, an α 2-receptor agonist, has emerged as a promising adjunct sedative for ESD under moderate sedation, offering anxiolysis and analgesia. We conducted a systematic review and meta-analysis to evaluate its efficacy and safety for use in ESD.

Methods: A comprehensive systematic search was conducted across multiple databases, including Embase, Medline, Scopus, and Web of Science. Studies that involved ESD utilizing dexmedetomidine as an adjunctive medication in combination with other sedatives, were included. Data extraction and risk of bias assessment were independently performed by two reviewers. Meta-analysis was carried out with RevMan using a random-effects model.

Results: Eight studies were included in the final analysis. Dexmedetomidine showed no significant difference in en-bloc or complete resection rates compared to controls. Sedation and procedure times were similar between the two groups as well. Dexmedetomidine significantly reduced restlessness (OR 0.15, 95% CI:0.07 to 0.29) and increased bradycardia (OR 7.15, 95% CI 3.17 to 16.11) compared to controls. Upon subgroup analysis, Dexmedetomidine plus Propofol, and Dexmedetomidine plus Midazolam, revealed the same findings regarding restlessness and bradycardia compared to controls which confirmed the adjunctive effects of Dexmedetomidine.

Conclusions: Dexmedetomidine as an adjunctive sedative appears safe and effective in ESD, reducing restlessness without significant adverse events. The risk of bradycardia is increased, which may be reflective of reduced physiological stress. Future studies should explore optimal dosing and compare Dexmedetomidine with other sedatives in diverse populations.

Keywords: Endoscopic Submucosal Dissection; Dexmedetomidine; Sedation; Dysplastic GI Lesions

It is made available under a CC-BY-ND 4.0 International license .

1. Introduction:

Endoscopic tumor resection is one of the most common modalities in GI tumor management. Endoscopic submucosal dissection (ESD) is considered superior to mucosal resection in view of offering complete resection with negative histological margins irrespective of the size of the original lesion [1] Despite these overwhelming advantages, ESD is associated with multiple postoperative complications including bleeding, postoperative perforation, and minor complications like abdominal pain, nausea, vomiting, and stricture which limits its use [2]. post-operative abdominal pain is a debilitating complication associated with ESD which is severely underestimated and results in decreased patient satisfaction and longer hospital stays. Studies show the incidence of postoperative pain in 44.9~62.8% of patients, especially in the early post-operative period necessitating the use of aggressive pain management [3,4].

Dexmedetomidine is a new α 2-receptor agonist that has anxiolytic, sedative, and analgesic properties which when used in combination with other anesthetics help lower their dose and also decrease postoperative opioid consumption and pain intensity [5,6]. A study done by Chang et al., also shows a better cardiovascular profile of dexmedetomidine as compared to propofol [7].

In our study, we reviewed the possible benefits of dexmedetomidine as an adjunct sedative perioperatively in patients undergoing ESD for GI adenomas and early-stage neoplastic lesions. We evaluated its efficacy by assessing variables like en-bloc resection, Complete resection, sedation time, procedure time, patient restlessness, and other adverse events.

2. Methods:

2.1. Search Strategy and Data Extraction:

A systematic search of relevant literature was conducted across multiple databases, including Embase, Scopus, Web of Science, Medline/PubMed, and Cochrane, from their inception to February 28, 2024. The search strategy utilized Boolean operators to combine terms related to the population, intervention, and outcomes of interest. The following search strategy was employed: ("endoscopic submucosal dissection" OR "ESD" OR "submucosal dissection") AND ("dexmedetomidine" OR "dexmedetomidine" OR "sedative") (**Appendix 1**). The search strategy aimed to identify studies investigating the use of dexmedetomidine as an adjunctive sedative in endoscopic submucosal dissection procedures. Our research adhered to the recommended guidelines for reporting systematic reviews and meta-analyses. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist and Cochrane criteria were followed to ensure transparency and completeness in reporting [8,9].

Two independent reviewers screened titles, abstracts, and full-text articles for inclusion based on predefined eligibility criteria. Any disagreements were resolved through discussion or consultation with a third reviewer. Data extraction was conducted independently by two co-authors using a standardized data extraction form, with

It is made available under a CC-BY-ND 4.0 International license .

discrepancies resolved through consensus. Extracted data included study characteristics, patient demographics, details of the intervention and comparator, and outcomes of interest.

2.2. Inclusion Criteria and Study Outcomes:

Studies eligible for inclusion in this meta-analysis were those focusing on patients who had gastrointestinal adenomas and early-stage neoplastic lesions eligible for endoscopic submucosal dissection (ESD) treatment. The intervention of interest was the use of dexmedetomidine as an adjunctive medication in combination with other sedatives in submucosal endoscopic dissection. There was no specific comparator for this review. The primary outcome of interest was the en-bloc resection. Secondary outcomes included Complete resection, sedative time, procedure time, restlessness, and different adverse events. Included study designs were randomized controlled trials (RCTs) and observational studies if applicable. Studies not written in English or with inadequate translation, Systematic reviews, Meta-analyses, Case reports, editorials, letters, or conference abstracts without full-text availability, animal studies, or studies conducted on non-human subjects were excluded.

2.3. Risk of Bias Assessment:

The risk of bias and methodological quality of the included studies was assessed independently by two authors. The Cochrane risk-of-bias tool version 2, (ROB 2) was employed for RCTs. For observational studies, we used the Newcastle-Ottawa Scale, any discrepancies were resolved through discussion or consultation with a third reviewer [10].

2.4. Statistical Analysis:

A meta-analysis was conducted using Review Manager 5.4 (Cochrane Collaboration, Copenhagen, The Nordic Cochrane Centre). Given the anticipated heterogeneity in study designs and populations, a random-effects model was utilized. Summary measures were expressed as pooled odds ratios (OR) with corresponding 95% confidence intervals (CI) for proportional variables and mean differences with corresponding 95% CIs for continuous variables. Statistical significance was set at a p-value <0.05. Heterogeneity was assessed using the I2 statistic, with an I2 value of \geq 50% indicating significant heterogeneity defined by the Cochrane Handbook for systematic reviews [11].

3. Results:

3.1. Search results:

The initial search retrieved 216 studies, 104 of them underwent title and abstract screening, and 25 full texts were assessed for inclusion. Eight studies were included in our final analysis (**Figure 1**).

3.2. Study and patient characteristics:

A total of 836 patients were included in our meta-analysis. Of the 836 patients, 412 (49.2%) were assigned to the Dexmedetomidine group, whereas 424 (50.7%) were assigned to the placebo group.

The included eight studies' characteristics are displayed in (Table 1).

3.3. Quality of included studies:

Quality assessment of included studies was assessed using (the Cochrane RoB 2 tool) for Randomized clinical trials. Four studies had a total low risk of bias, and one study had a moderate risk of bias. Another three Cohort studies were assessed using the Newcastle–Ottawa Scale with a low risk of bias (**Appendix 2**).

3.4. Meta-analysis outcomes:

1- En-bloc resection:

The data from 7 studies were analyzed for En-bloc resection, the odds ratio was 1.45 with a 95% confidence interval (CI) of 0.47 to 4.41 which revealed no significant difference between the two groups (p=0.52) at random effect as shown in **Figure 2**.

2- Complete resection:

Three studies reported a complete resection rate, and the odds ratio was 0.62 with a 95% confidence interval (CI) of 0.21 to 1.80 which revealed no significant difference between the two groups (p=0.38) as shown in **Figure 3**.

3- Sedation time:

The pooled results from four studies reporting on sedation time revealed that there was no significant difference between the two groups, as shown in **Figure 4** (MD: 6.81, 95% CI: -2.25-15.87; $I^2 0\%$; P=0.14).

4- Procedure Time:

Five studies reporting on procedure time revealed that there was no significant difference between the two groups as shown in **Figure 5** (MD: 3.21, 95% CI: -6.32-12.74; $I^2 0\%$; P=0.51).

5- Restlessness:

Four studies reported a restlessness rate, the odds ratio was 0.15 with a 95% confidence interval (CI) of 0.07 to 0.29 which revealed a significant difference between the two groups (p<0.00001). as shown in **Figure 6**.

6- Bradycardia:

Seven studies reported the bradycardia rate, and the odds ratio was 7.15 with a 95% confidence interval (CI) of 3.17 to 16.11 which revealed a significant difference between the two groups (p<0.00001) as shown in **Figure** 7.

It is made available under a CC-BY-ND 4.0 International license .

7- Hypoxia:

Four studies reported the Hypoxia rate and the odds ratio was 0.95 with a 95% confidence interval (CI) of 0.38 to 2.36 which revealed no significant difference between the two groups (p=0.91) as shown in **Figure 8**.

8- Hypotension:

Seven studies reported the Hypotension rate and the odds ratio was 2.73 with a 95% confidence interval (CI) of 0.79 to 9.43 which revealed no significant difference between the two groups (p=0.11) as shown in **Figure 9**.

9- Perforation:

Five studies reported the perforation rate and the odds ratio was 0.51 with a 95% confidence interval (CI) of 0.05 to 5.44 which revealed no significant difference between the two groups (p=0.58) as shown in **Figure 10**.

10- Bleeding:

Three studies reported the Bleeding rate, the odds ratio was 0.41 with a 95% confidence interval (CI) of 0.12 to 1.39 which revealed no significant difference between the two groups (p=0.15) as shown in **Figure 11**.

3.5. Subgroup Analysis Outcomes:

- 1- Dexmedetomidine + Propofol:
- **1.1.** En-bloc resection (Dexmedetomidine + Propofol):

Two studies reported en-bloc resection rate for Dexmedetomidine in combination with propofol, the odds ratio was 3.09 with a 95% confidence interval (CI) of 0.12 to 78.70 which revealed no significant difference between the two groups (p=0.49) as shown in **Figure 12**.

1.2. Complete resection (Dexmedetomidine + Propofol):

Two studies reported a complete resection rate for Dexmedetomidine in combination with propofol, the odds ratio was 0.72 with a 95% confidence interval (CI) of .23 to 2,24 which revealed no significant difference between the two groups (p=0.57) as shown in **Figure 13**.

1.3. Procedure Time (Dexmedetomidine + Propofol):

Two studies reporting on procedure time for Dexmedetomidine in combination with propofol revealed that there was no significant difference between the two groups as shown in **Figure 14** (MD: -4.05, 95% CI: -27.57-19.47; I^2 =63%; P=0.74).

It is made available under a CC-BY-ND 4.0 International license .

1.4. Restlessness (Dexmedetomidine + Propofol):

Two studies reported Restlessness for Dexmedetomidine in combination with propofol, the odds ratio was 0.14 with a 95% confidence interval (CI) of 0.05 to 0.45 which revealed a significant difference between the two groups (p=0.0009) as shown in **Figure 15**.

1.5. Bradycardia (Dexmedetomidine + Propofol):

Two studies reported Bradycardia for Dexmedetomidine in combination with propofol, the odds ratio was 10.04 with a 95% confidence interval (CI) of 2.92 to 34.54 which revealed a significant difference between the two groups (p=0.0003) as shown in **Figure 16**.

1.6. *Hypoxemia* (*Dexmedetomidine* + *Propofol*):

Two studies reported hypoxemia for Dexmedetomidine in combination with propofol, the odds ratio was 0.28 with a 95% confidence interval (CI) of 0.11 to 0.71 which revealed a significant difference between the two groups (p=0.007) as shown in **Figure 17**.

1.7. Hypotension (*Dexmedetomidine* + *Propofol*):

Two studies reported Hypotension for Dexmedetomidine in combination with propofol, the odds ratio was 3.83 with a 95% confidence interval (CI) of 1.00 to 14.69 which revealed a significant difference between the two groups (p=0.05) as shown in **Figure 18**.

2- Dex + Midazolam:

2.1. En-bloc resection (Dex + Midazolam):

Two studies reported en-bloc resection for Dexmedetomidine in combination with Midazolam, the odds ratio was 1.80 with a 95% confidence interval (CI) of 0.50 to 6.51 which revealed no significant difference between the two groups (p=0.37) as shown in **Figure 19**.

2.2. Restlessness (Dex + Midazolam):

Two studies reported Restlessness for Dexmedetomidine in combination with Midazolam, the odds ratio was 0.15 with a 95% confidence interval (CI) of 0.06 to 0.35 which revealed a significant difference between the two groups (p < 0.0001) as shown in **Figure 20**.

It is made available under a CC-BY-ND 4.0 International license .

2.3. Bradycardia (Dex + Midazolam):

Two studies reported Bradycardia for Dexmedetomidine in combination with Midazolam, the odds ratio was 14.97 with a 95% confidence interval (CI) of 2.44 to 91.68 which revealed a significant difference between the two groups (p=0.003) as shown in **Figure 21**.

2.4. Hypoxia (Dex + Midazolam):

Two studies reported Hypoxia for Dexmedetomidine in combination with Midazolam, the odds ratio was 0.80 with a 95% confidence interval (CI) of 0.33 to 1.94 which revealed no significant difference between the two groups (p=0.62) as shown in **Figure 22**.

2.5. Bleeding (Dex + Midazolam):

Two studies reported Bleeding for Dexmedetomidine in combination with Midazolam, the odds ratio was 0.42 with a 95% confidence interval (CI) of 0.11 to 1.60 which revealed no significant difference between the two groups (p=0.20) as shown in **Figure 23**.

2.6. Perforation (Dex + Midazolam):

Two studies reported Perforation for Dexmedetomidine in combination with Midazolam, the odds ratio was 0.24 with a 95% confidence interval (CI) of 0.01 to 4.13 which revealed no significant difference between the two groups (p=0.32) as shown in **Figure 24**.

4. Discussion

Although the debilitating pain associated with ESD warrants aggressive pain management, physicians are hesitant due to the possibility of masking the pain of perforation. This not only causes patient discomfort but also increases the burden on healthcare by prolonging discharge time [2,4]. A study done by Seiichiro et al. shows an increased incidence of metachronous gastric cancer in patients who underwent curative ESD of early gastric cancer [12]. These warrant further endoscopic surveillance and possible repeat ESD. However, poorly managed post-operative pain increases apprehension in patients for further endoscopic procedures. As previously described, a few studies have been done describing the incidence of postoperative pain after ESD but there is no consensus on the management of the said pain. Studies done by Lee and Kim recommend a single dose of dexamethasone or postoperative local bupivacaine and triamcinolone [13,14].

In our study, we found a significant reduction in restlessness and bradycardia associated with dexmedetomidine highlighting its potential as an effective sedative agent for endoscopic procedures. We also observed a statistically significant decrease in tachycardia which could indicate less anxiety and pain thus providing a more comfortable sedative experience for the patients. These properties could be attributed to its selective alpha 2 adrenergic agonist and sympatholytic properties [15]. The non-significant difference found in en bloc resection

rates between dexmedetomidine, and the comparator groups alleviated concerns regarding the influence of the sedation regimen on the technical aspects of the procedure [16].

The subgroup analysis also revealed better outcomes particularly in terms of reduced restlessness and bradycardia, with Dexmedetomidine in combination with Midazolam compared to other combinations. The anxiolytic and amnestic properties of Midazolam, coupled with the sedative and analgesic effects of Dexmedetomidine, may offer superior patient comfort and procedural tolerance. Additionally, considering the favorable safety profile of Midazolam in terms of respiratory depression compared to Propofol, this combination presents a compelling option for optimizing sedation strategies in endoscopic settings [17].

Our review suggests that dexmedetomidine is an effective sedative agent for ESD. Lee et al. [18] on the other hand, compared the outcomes of sedation using dexmedetomidine infusion plus on-demand midazolam versus sedation using midazolam infusion plus on-demand midazolam. They concluded that the sedation effect of dexmedetomidine with midazolam was superior to the sedation effect with midazolam alone. Furthermore, four studies reported sedation time as an outcome, while five studies reported procedure time as an outcome, **Figure 4** and **Figure 5**. The pooled results from these studies showed no statistically significant difference in sedation or procedure time between the dexmedetomidine and the control group. Despite the significant reduction in intraoperative restlessness in the dexmedetomidine group in our review, as mentioned above, this did not translate into a shorter sedation or procedure time, (**Figure 6**).

Nonaka et al. [19] reported a significantly shorter procedure time in the combination group (dexmedetomidine and propofol) compared to the benzodiazepine group; nevertheless, this finding was lost after pooling with other studies in the analysis, as shown in **Figure 5**.

In terms of safety, our findings support the use of dexmedetomidine as an adjunctive agent in procedural sedation for ESD procedures, consistent with previous studies [20,21]. As noted by Candiotti et al. [20], the Dexmedetomidine group demonstrated a higher incidence of bradycardia, as illustrated in **Figure 7**. However, there was no statistically significant increase in the occurrence of other adverse events such as hypoxia, hypotension, bleeding, or perforation. Additionally, Dexmedetomidine's cardiovascular and hemodynamic effects are well-known and are attributed to its strong alpha 2-adrenergic agonist effect and include bradycardia, hypotension, and hypoxia [20-23]. Kim et al. evaluated risk factors for dexmedetomidine-associated bradycardia during spinal anesthesia [23] and found that a long tourniquet time and low baseline heart rate were associated with an increased incidence of bradycardia during procedures under spinal anesthesia. Notably, Alshikaria [24] et al. reported that no serious adverse events were observed in patients in the dexmedetomidine group who experienced bradycardia and that their clinical outcomes were not altered due to it, which is also consistent with previous literature [25,26].

The use of Dexmedetomidine as an adjunctive sedative has shown promising results in our meta-analysis, yet this type of intervention needs further exploration. The included studies in this review have already explored the combination of Dexmedetomidine with the two main sedatives, propofol and midazolam. The results are extraordinary in terms of restlessness and bradycardia incidence, the latter being a good sign of less stress and discomfort during the procedure. Less movements (restlessness) during the ESD procedure leads to more convenient and accurate procedures from the operator. So, this therapy should be explored more to reach the best results possible for the patient. More exploration means more multicenter randomized controlled trials and

It is made available under a CC-BY-ND 4.0 International license .

observational studies comparing this type of adjunctive therapy with other adjunctive sedatives and even other types of pain management methods, like local anesthesia in the region of intervention, to test this intervention's safety and efficacy to standardize its use during ESD procedures in the near future.

Limitations: To our knowledge, this is the first meta-analysis to assess the safety and efficacy of Dexmedetomidine as an adjunctive sedative after ESD. Additionally, we performed subgroup analysis according to each general therapy. Most included articles (6 out of 8) did not conduct a head-to-head comparison between dexmedetomidine and other agents. Also, the limited number of published clinical trials and the number of patients included in certain subgroups make our evidence and conclusions limited on some outcomes. All of our eight included trials were conducted in eastern Asia, including 5 in Japan, two in Korea, and one in China. Thus, the generalizability of this study results to other regions with different ethnicities and medical environments may be affected. A standardized dosage of dexmedetomidine as an adjuvant sedative has not yet been established, resulting in a wide variety of dexmedetomidine regimens.

5. Conclusions:

In conclusion, our meta-analysis supports the safe use of dexmedetomidine as an adjunctive sedative in ESD procedures. Dexmedetomidine, when combined with other sedatives, appears to reduce restlessness without increasing the risk of hypoxia, hypotension, bleeding, or perforation. The increased risk of bradycardia noted with dexmedetomidine can be perceived as less physiological stress and tachycardia during procedures. However, our findings are limited by the lack of direct comparisons with other sedatives and the predominantly Eastern Asian study populations. Further research, including multicenter trials, is needed to establish optimal dosing regimens and evaluate dexmedetomidine's efficacy compared to other sedatives and pain management methods in diverse patient populations.

6. Declarations:

Conflicts of Interest: N/A.

IRB Approval: N/A.

Funding Source: The project described was supported by the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, through CTSA award number: UM1TR004400. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Ethical Approvals: N/A.

Consent for Participation: N/A.

It is made available under a CC-BY-ND 4.0 International license .

References:

1. Isomoto H, Shikuwa S, Yamaguchi N, et al.: Endoscopic submucosal dissection for early gastric cancer: a large-scale feasibility study. Gut. 2009, 58:331-336. 10.1136/gut.2008.165381

2. Nishizawa T, Yahagi N: Endoscopic mucosal resection and endoscopic submucosal dissection: technique and new directions. Curr Opin Gastroenterol. 2017, 33:315-319. 10.1097/mog.00000000000388

3. Luo X, An LX, Chen PS, Chang XL, Li Y: Efficacy of dexmedetomidine on postoperative pain in patients undergoing gastric and esophageal endoscopic submucosal dissection: a study protocol for a randomized controlled prospective trial. Trials. 2022, 23:491. 10.1186/s13063-022-06432-4

4. Kim JW, Jang JY, Park YM, Shim JJ, Chang YW: Clinicopathological characteristics of patients with pain after endoscopic submucosal dissection for gastric epithelial neoplasm. Surg Endosc. 2019, 33:794-801. 10.1007/s00464-018-6345-3

5. Ramsay MA, Luterman DL: Dexmedetomidine as a total intravenous anesthetic agent. Anesthesiology. 2004, 101:787-790. 10.1097/00000542-200409000-00028

6. Liu Y, Liang F, Liu X, Shao X, Jiang N, Gan X: Dexmedetomidine Reduces Perioperative Opioid Consumption and Postoperative Pain Intensity in Neurosurgery: A Meta-analysis. J Neurosurg Anesthesiol. 2018, 30:146-155. 10.1097/ana.000000000000403

7. Chang ET, Certal V, Song SA, et al.: Dexmedetomidine versus propofol during drug-induced sleep endoscopy and sedation: a systematic review. Sleep Breath. 2017, 21:727-735. 10.1007/s11325-017-1465-x

8. Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. Int J Surg. 2010, 8:336-341. 10.1016/j.ijsu.2010.02.007

9. Cumpston M, Li T, Page MJ, et al.: Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019, 10:Ed000142. 10.1002/14651858.Ed000142

10. Sterne JAC, Savović J, Page MJ, et al.: RoB 2: a revised tool for assessing risk of bias in randomised trials. Bmj. 2019, 366:14898. 10.1136/bmj.14898

11. Deeks JJ, Bossuyt PM, Leeflang MM, Takwoingi Y (editors). Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy. Version 2.0 (updated July 2023). Cochrane, 2023. Available from https://training.cochrane.org/handbook-diagnostic-test-accuracy/current

12. Abe S, Oda I, Suzuki H, et al.: Long-term surveillance and treatment outcomes of metachronous gastric cancer occurring after curative endoscopic submucosal dissection. Endoscopy. 2015, 47:1113-1118. 10.1055/s-0034-1392484

13. Lee HW, Lee H, Chung H, et al.: The efficacy of single-dose postoperative intravenous dexamethasone for pain relief after endoscopic submucosal dissection for gastric neoplasm. Surg Endosc. 2014, 28:2334-2341. 10.1007/s00464-014-3463-4

14. Kim B, Lee H, Chung H, et al.: The efficacy of topical bupivacaine and triamcinolone acetonide injection in the relief of pain after endoscopic submucosal dissection for gastric neoplasia: a randomized double-blind, placebo-controlled trial. Surg Endosc. 2015, 29:714-722. 10.1007/s00464-014-3730-4

15. Afonso J, Reis F: Dexmedetomidine: current role in anesthesia and intensive care. Rev Bras Anestesiol. 2012, 62:118-133. 10.1016/s0034-7094(12)70110-1

16. Dumoulin FL, Hildenbrand R: Endoscopic resection techniques for colorectal neoplasia: Current developments. World J Gastroenterol. 2019, 25:300-307. 10.3748/wjg.v25.i3.300

17. Yoshio T, Ishiyama A, Tsuchida T, et al.: Efficacy of novel sedation using the combination of dexmedetomidine and midazolam during endoscopic submucosal dissection for esophageal squamous cell carcinoma. Esophagus. 2019, 16:285-291. 10.1007/s10388-019-00666-z

18. Lee SP, Sung IK, Kim JH, et al.: Comparison of dexmedetomidine with on-demand midazolam versus midazolam alone for procedural sedation during endoscopic submucosal dissection of gastric tumor. J Dig Dis. 2015, 16:377-384. 10.1111/1751-2980.12254

19. Nonaka T, Inamori M, Miyashita T, et al.: Feasibility of deep sedation with a combination of propofol and dexmedetomidine hydrochloride for esophageal endoscopic submucosal dissection. Dig Endosc. 2016, 28:145-151. 10.1111/den.12559

20. Candiotti KA, Bergese SD, Bokesch PM, Feldman MA, Wisemandle W, Bekker AY: Monitored anesthesia care with dexmedetomidine: a prospective, randomized, double-blind, multicenter trial. Anesth Analg. 2010, 110:47-56. 10.1213/ane.0b013e3181ae0856

21. Riker RR, Shehabi Y, Bokesch PM, et al.: Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. Jama. 2009, 301:489-499. 10.1001/jama.2009.56

22. Bloor BC, Ward DS, Belleville JP, Maze M: Effects of intravenous dexmedetomidine in humans. II. Hemodynamic changes. Anesthesiology. 1992, 77:1134-1142. 10.1097/00000542-199212000-00014

23. Kim HJ, Ahn E: Risk factors for dexmedetomidine-associated bradycardia during spinal anesthesia: A retrospective study. Medicine (Baltimore). 2022, 101:e31306. 10.1097/md.000000000031306

24. Ashikari K, Nonaka T, Higurashi T, et al.: Efficacy of sedation with dexmedetomidine plus propofol during esophageal endoscopic submucosal dissection. J Gastroenterol Hepatol. 2021, 36:1920-1926. 10.1111/jgh.15417
25. Mason KP, Robinson F, Fontaine P, Prescilla R: Dexmedetomidine offers an option for safe and effective sedation for nuclear medicine imaging in children. Radiology. 2013, 267:911-917. 10.1148/radiol.13121232
26. Talon MD, Woodson LC, Sherwood ER, Aarsland A, McRae L, Benham T: Intranasal dexmedetomidine premedication is comparable with midazolam in burn children undergoing reconstructive surgery. J Burn Care Res. 2009, 30:599-605. 10.1097/BCR.0b013e3181abff90

It is made available under a CC-BY-ND 4.0 International license .

Figures Legend:

Figure 1: PRISMA flow diagram of the search strategy.

It is made available under a CC-BY-ND 4.0 International license .



It is made available under a CC-BY-ND 4.0 International license .

Figure 2: En-bloc resection.

	Favours control Control					Odds Ratio	Odds Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI		IV, Random, 95% CI	
Ashikari 2021	33	33	32	33	11.9%	3.09 [0.12, 78.70]			
lwagami 2023	151	155	126	132	75.0%	1.80 [0.50, 6.51]			
Kim 2015	34	36	32	32	13.1%	0.21 [0.01, 4.59]			
Kinugasa 2018	40	40	40	40		Not estimable			
Lee 2015	40	40	40	40		Not estimable			
Nonaka 2016	20	20	20	20		Not estimable			
Yoshio 2019	65	65	99	99		Not estimable			
Total (95% CI)		389		396	100.0%	1.45 [0.47, 4.41]			
Total events	383		389						
Heterogeneity: Tau ² =	0.00; Chi ² =	1.82, df	= 2 (P = I	0.40); P	²= 0%		-		
Test for overall effect:	Z = 0.65 (P =	= 0.52)					0.01	Favours control Favours Dexmedetomidine	

Figure 3: Complete resection.

	Dex as adjur	ictive	Cont	rol		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Ashikari 2021	28	33	29	33	56.8%	0.77 [0.19, 3.18]	
Kim 2015	34	36	32	32	12.0%	0.21 [0.01, 4.59]	
Nonaka 2016	17	20	18	20	31.2%	0.63 [0.09, 4.24]	
Total (95% CI)		89		85	100.0%	0.62 [0.21, 1.80]	-
Total events	79		79				
Heterogeneity: Tau ² =	0.00; Chi ² = 0.	56, df=	2 (P = 0.3	76); l² =	0%		
Test for overall effect:	Z = 0.88 (P = 0	1.38)				Favours Control Favours Dexmedetomidine	

Figure 4: Sedation time.

	Exp	Experimental Control						Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Ashikari 2021	173.06	198.63	33	210.74	295.72	33	0.6%	-37.68 [-159.22, 83.86]	
Kim 2015	42.8	26.7	29	37.6	18.5	30	59.3%	5.20 [-6.56, 16.96]	
Luo 2023	107.37	54.68	30	102.16	46.47	30	12.4%	5.21 [-20.47, 30.89]	
Yoshio 2019	112.27	62.96	65	100.4	40.07	99	27.7%	11.87 [-5.35, 29.09]	+
Total (95% CI)			157			192	100.0%	6.81 [-2.25, 15.87]	•
Heterogeneity: Tau ² = 0.00; Chi ² = 0.93, df = 3 (P = 0.82); l ² = 0% Test for overall effect: Z = 1.47 (P = 0.14)									-100 -50 0 50 100 Favours Dexmedetomidine Favours Control

Figure 5: Procedure Time.

	Dexm	Dexmedetomidine Control						Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Ashikari 2021	57.54	33.42	33	51.92	22.12	33	48.6%	5.62 [-8.05, 19.29]	
Kinugasa 2018	95.08	74.97	40	92.53	49.98	40	11.6%	2.55 [-25.37, 30.47]	_
Lee 2015	114.4	74.8	40	100.5	68.5	40	9.2%	13.90 [-17.53, 45.33]	_ +-
Luo 2023	67.31	49.42	30	58.96	40.86	30	17.2%	8.35 [-14.60, 31.30]	_ _
Nonaka 2016	77.49	45.76	20	96.43	38	20	13.4%	-18.94 [-45.01, 7.13]	
Total (95% CI)			163			163	100.0%	3.21 [-6.32, 12.74]	•
Heterogeneity: Tau ² =	0.00; Ch	i ř = 3.53,	df = 4						
Test for overall effect:	Z = 0.66	(P = 0.51)	Favours Dexmedetomidine Favours Control					

Figure 6: Restlessness.

It is made available under a CC-BY-ND 4.0 International license .

	Experim	ental	Contr	ol		Odds Ratio	Odds R	atio	
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI	IV, Random	i, 95% Cl	
Ashikari 2021	1	33	9	33	10.5%	0.08 [0.01, 0.70]			
Lee 2015	21	40	34	40	42.0%	0.20 [0.07, 0.57]			
Nonaka 2016	5	20	13	20	25.6%	0.18 [0.05, 0.70]	_		
Yoshio 2019	2	65	27	99	21.9%	0.08 [0.02, 0.37]			
Total (95% CI)		158		192	100.0%	0.15 [0.07, 0.29]	•		
Total events	29		83						
Heterogeneity: Tau² =	= 0.00; Chi ^a	² = 1.16,	df = 3 (P	= 0.76)); I² = 0%				1000
Test for overall effect:	Z=5.47 (♀ < 0.00	001)			Favours Dexmedetomidine	Favours Control	1000	

Figure 7: Bradycardia.

	Experim	mental Control				Odds Ratio	Odds Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI	IV, Rando	m, 95% Cl	
Ashikari 2021	10	33	1	33	13.1%	13.91 [1.66, 116.41]			
lwagami 2023	4	155	0	132	7.3%	7.87 [0.42, 147.56]			-
Kinugasa 2018	3	40	0	40	7.0%	7.56 [0.38, 151.28]			-
Lee 2015	5	40	1	40	12.4%	5.57 [0.62, 50.03]	-		
Luo 2023	8	30	4	30	29.0%	2.36 [0.63, 8.92]	-		
Nonaka 2016	12	20	3	20	23.4%	8.50 [1.86, 38.82]			
Yoshio 2019	23	65	0	99	7.8%	110.04 [6.53, 1853.58]			
Total (95% CI)		383		394	100.0%	7.15 [3.17, 16.11]		•	
Total events	65		9						
Heterogeneity: Tau ² =	: 0.13; Chi ^a	= 6.73,	df = 6 (P	= 0.35)	; I² = 11%)			1000
Test for overall effect:	Z=4.74 (F	0.00 <	001)				Favours Dexmedetomidine	Favours Control	1000

Figure 8: Hypoxia.

	Experim	Experimental Control				Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
lwagami 2023	17	155	8	132	30.9%	1.91 [0.80, 4.58]	
Kinugasa 2018	3	40	0	40	7.6%	7.56 [0.38, 151.28]	
Lee 2015	7	40	11	40	27.1%	0.56 [0.19, 1.63]	
Yoshio 2019	15	65	38	99	34.3%	0.48 [0.24, 0.97]	
Total (95% CI)		300		311	100.0%	0.95 [0.38, 2.36]	+
Total events	42		57				
Heterogeneity: Tau ² =	0.50; Chi ²	= 8.38,	df = 3 (P	= 0.04)); I ² = 64%	, ,	
Test for overall effect:	Z = 0.12 (F	° = 0.91)				Favours Dexmedetomidine Favours Control

Figure 9: Hypotension.

	Experim	ental	Contr	ol		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Ashikari 2021	12	33	7	33	17.2%	2.12 [0.71, 6.35]	
lwagami 2023	10	155	0	132	9.7%	19.12 [1.11, 329.54]	
Kinugasa 2018	2	40	0	40	9.0%	5.26 [0.24, 113.11]	
Lee 2015	3	40	2	40	13.8%	1.54 [0.24, 9.75]	-
Luo 2023	5	30	16	30	16.8%	0.17 [0.05, 0.58]	-
Nonaka 2016	12	20	3	20	15.3%	8.50 [1.86, 38.82]	
Yoshio 2019	24	65	8	99	18.1%	6.66 [2.76, 16.07]	_ _ _
Total (95% CI)		383		394	100.0%	2.73 [0.79, 9.43]	-
Total events	68		36				
Heterogeneity: Tau ² =	2.01; Chi ²	= 28.69	9, df = 6 (F	° < 0.0	001); I 2 = 1	79%	
Test for overall effect:	Z = 1.59 (F	^o = 0.11)				Eavoure Devmedeternidine Eavoure Control
							Favours Devinedetorniune Favours Control

It is made available under a CC-BY-ND 4.0 International license .

Figure 10: Perforation.

	Experime	ental	Contr	ol		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Ashikari 2021	0	33	0	33		Not estimable	
lwagami 2023	0	155	7	132	34.5%	0.05 [0.00, 0.95]	
Kinugasa 2018	0	40	0	40		Not estimable	
Lee 2015	1	40	1	40	35.4%	1.00 [0.06, 16.56]	_
Nonaka 2016	1	20	0	20	30.1%	3.15 [0.12, 82.16]	
Total (95% CI)		288		265	100.0%	0.51 [0.05, 5.44]	
Total events	2		8				
Heterogeneity: Tau ² =	2.04; Chi ^z	= 3.77,	df = 2 (P	= 0.15)); l² = 47%	, ,	
Test for overall effect:	Z=0.55 (F	P = 0.58)	Favours Dexmedetomidine Favours Control			

Figure 11: Bleeding.

	Experim	ental	Contr	ol		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
lwagami 2023	0	155	1	132	14.7%	0.28 [0.01, 6.98]	
Lee 2015	3	40	6	40	71.0%	0.46 [0.11, 1.98]	
Nonaka 2016	0	20	1	20	14.3%	0.32 [0.01, 8.26]	
Total (95% CI)		215		192	100.0%	0.41 [0.12, 1.39]	-
Total events	3		8				
Heterogeneity: Tau ² =	0.00; Chi ^a	= 0.10,	df = 2 (P	= 0.95)); I² = 0%		
Test for overall effect:	Z = 1.44 (F	° = 0.15)				Favours Dexmedetomidine Favours Control

Figure 12: En-bloc resection (Dexmedetomidine + Propofol).

	Experimental		Control			Odds Ratio	Odds Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl		
Ashikari 2021	33	33	32	33	100.0%	3.09 [0.12, 78.70]			
Nonaka 2016	20	20	20	20		Not estimable			
Total (95% CI) Total events Heterogeneity: Not ap Test for overall effect:	53 plicable Z = 0.68 (f	53 ⁻ = 0.49	52	53	100.0%	3.09 [0.12, 78.70]	0.001 0.1 1 10 1000 Favours control Favours Dex+Propofol		

Figure 13: Complete resection (Dexmedetomidine + Propofol).

	Experim	ental	Cont	rol		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Ashikari 2021	28	33	29	33	64.6%	0.77 [0.19, 3.18]	— —
Nonaka 2016	17	20	18	20	35.4%	0.63 [0.09, 4.24]	
Total (95% CI)		53		53	100.0%	0.72 [0.23, 2.24]	-
Total events	45		47				
Heterogeneity: Tau² = Test for overall effect:	: 0.00; Chi ^a Z = 0.57 (F	² = 0.03, P = 0.57	df = 1 (P)	= 0.87)); I² = 0%		0.001 0.1 1 10 1000 Favours control Favours Dex+Propofol

It is made available under a CC-BY-ND 4.0 International license .

Figure 14: Procedure Time (Dexmedetomidine + Propofol).



Figure 15: Restlessness (Dexmedetomidine + Propofol).



Figure 16: Bradycardia (Dexmedetomidine + Propofol).

	Experim	ental	Cont	ol	Odds Ratio		Odds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI	
Ashikari 2021	10	33	1	33	33.8%	13.91 [1.66, 116.41]		
Nonaka 2016	12	20	3	20	66.2%	8.50 [1.86, 38.82]	│ — ∎ —	
Total (95% CI)		53		53	100.0%	10.04 [2.92, 34.54]	-	
Total events	22		4					
Heterogeneity: Tau ² = 0.00; Chi ² = 0.14, df = 1 (P = 0.71); I ² = 0%								1000
Test for overall effect:	Z=3.66 (A	P = 0.00	03)				Eavours Dex+Propofol Favours Control	1000

Figure 17: Hypoxemia (Dexmedetomidine + Propofol).

	Experim	ental	Contr	ol		Odds Ratio	Odds	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% Cl	IV, Rando	om, 95% Cl	
Ashikari 2021	6	33	13	33	69.8%	0.34 [0.11, 1.06]		+	
Nonaka 2016	2	20	8	20	30.2%	0.17 [0.03, 0.92]		-	
Total (95% CI)		53		53	100.0%	0.28 [0.11, 0.71]	•		
Total events	8		21						
Heterogeneity: Tau² = Test for overall effect:	0.00; Chi ^z Z = 2.69 (F	e = 0.47, P = 0.00	df = 1 (P 7)	= 0.49)	; I² = 0%		L 0.001 0.1 Favours Dex+Propofol	1 10 Favours Control	1000

Figure 18: Hypotension (Dexmedetomidine + Propofol).

It is made available under a CC-BY-ND 4.0 International license .

	Experim	ental	Control		Odds Ratio		Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
Ashikari 2021	12	33	7	33	57.5%	2.12 [0.71, 6.35]	+∎
Nonaka 2016	12	20	3	20	42.5%	8.50 [1.86, 38.82]	_
Total (95% CI)		53		53	100.0%	3.83 [1.00, 14.69]	
Total events	24		10				
Heterogeneity: Tau ² =	0.51; Chi²	= 2.11,	df = 1 (P	= 0.15)	; I² = 53%		
Test for overall effect:	Z=1.96 (F	P = 0.05)				Favours Dex+Propofol Favours Control

Figure 19: En-bloc resection (Dex + Midazolam).



Figure 20: Restlessness (Dex + Midazolam).

	Experim	ental	Control		Odds Ratio		Odds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% CI	
Lee 2015	21	40	34	40	65.7%	0.20 [0.07, 0.57]		
Yoshio 2019	2	65	27	99	34.3%	0.08 [0.02, 0.37]	_	
Total (95% CI)		105		139	100.0%	0.15 [0.06, 0.35]	◆	
Total events	23		61					
Heterogeneity: Tau ² = 0.00; Chi ² = 0.81, df = 1 (P = 0.37); I ² = 0%								
Test for overall effect: Z = 4.35 (P < 0.0001)							Favours Dex+Midazolam Favours Control	000

Figure 21: Bradycardia (Dex + Midazolam).

	Experim	ental	Contr	rol		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
lwagami 2023	4	155	0	132	28.3%	7.87 [0.42, 147.56]	
Lee 2015	5	40	1	40	41.9%	5.57 [0.62, 50.03]	
Yoshio 2019	23	65	0	99	29.9%	110.04 [6.53, 1853.58]	
Total (95% CI)		260		271	100.0%	14.97 [2.44, 91.68]	
Total events	32		1				
Heterogeneity: Tau ² =	0.79; Chi ^a	= 2.87,	df = 2 (P	= 0.24)); I ² = 30%		
Test for overall effect:	Z = 2.93 (P = 0.00	3)				Eavours Dex+Midazolam Eavours

Figure 22: Hypoxia (Dex + Midazolam).

It is made available under a CC-BY-ND 4.0 International license .

	Experim	ental	Contr	rol		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
lwagami 2023	17	155	8	132	33.5%	1.91 [0.80, 4.58]	+
Lee 2015	7	40	11	40	28.8%	0.56 [0.19, 1.63]	
Yoshio 2019	15	65	38	99	37.8%	0.48 [0.24, 0.97]	
Total (95% CI)		260		271	100.0%	0.80 [0.33, 1.94]	-
Total events	39		57				
Heterogeneity: Tau² = Test for overall effect:	0.41; Chi² Z = 0.50 (F	°= 6.19, °= 0.62	df = 2 (P)	= 0.05)); I² = 68%	1	0.001 0.1 1 10 1000 Favours Dex+Midazolam Favours Control

Figure 23: Bleeding (Dex + Midazolam).

	Experim	ental	Contr	ol		Odds Ratio	Odds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl	
lwagami 2023	0	155	1	132	17.2%	0.28 [0.01, 6.98]		
Lee 2015	3	40	6	40	82.8%	0.46 [0.11, 1.98]		
Total (95% CI)		195		172	100.0%	0.42 [0.11, 1.60]	-	
Total events	3		7					
Heterogeneity: Tau² = Test for overall effect:	0.00; Chi ^a Z = 1.27 (F	= 0.07, P = 0.20	df = 1 (P)	= 0.79)); I ^z = 0%		0.001 0.1 1 10 Favours Dex+Midazolam Favours Control	1000

Figure 24: Perforation (Dex + Midazolam).

	Experim	ental	Cont	rol		Odds Ratio	Odds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI	
lwagami 2023	0	155	7	132	49.4%	0.05 [0.00, 0.95]		
Lee 2015	1	40	1	40	50.6%	1.00 [0.06, 16.56]		
Total (95% CI)		195		172	100.0%	0.24 [0.01, 4.13]		
Total events	1		8					
Heterogeneity: Tau² = Test for overall effect:	2.17; Chi² Z = 0.99 (F	= 2.03, P = 0.32	df = 1 (P)	= 0.15)	; I² = 51%	5	0.001 0.1 1 10 Favours Dex+Midazolam Favours Control	1000

It is made available under a CC-BY-ND 4.0 International license .

Tables Legend:

Author	Countr	Study	Age mean		Intervention(t/contro	Procedur	Size of lesion	
	У	design	/(S	SD)	I)	e location	mean /(SD)	
			Ca	ases			Cases	contro
			cor	ntrol				1
Ashikari	Japan	RCT	21.25	22.97	propofol plus	superficial	68.86	8
2021			(8.29	(12.78	dexmedetomidine;	esophagea	(30.99)	(24.24)
))	propofol alone.	l cancers		
Iwagami	Japan	retrospective	NA	NA	Midazolam and	colorectal	64.4(38.2	85 (55)
2023		COHORT			pethidine	lesions)	
					hydrochloride + DEX;			
					Midazolam and			
					pethidine			
					nyarochioride			
Vim	Voraa	рст	62.9	65 1	Davmadatamidina	Econhogy	62.0	10
×1111 2015	Korea	KC I	02.8	(10.2)	remifentanil (DR):	Esophagu	(12.3)	10 (34.5)
2013			(0.5)	(10.2)	propofol-remifentanil	3	(12.3)	(34.3)
					(PR)			
Kinugas	Japan	RCT	22.4	22.5	Dex + Pethidine;	Colorectal	67.9	21
a 2018			(4.3)	(2.77)	Pethidine		(33.8)	(52%)
Lee	Korea	RCT	23.79	24.32	dexmedetomidine	Gastric	15	22.5
2015			((2.07)	(DEX) with on-	Tumor		
			2.70)		demand MDZ;			
					MDZ alone			
Luo	China	RCT	57 (55.8	Dex bolus +	Stomach -	3.4 (1.2)	2.8 (
2023			1)	(7.5)	maintenance intraop;	gastric		1.3)
					Normal saline			

 Table 1: Baseline Characteristics of The Included Studies.

It is made available under a CC-BY-ND 4.0 International license .

2016 (7.7) (8.5) proposed and day:	
2010 e (1.1) (0.3) proportion and dex, s	(15.2)
Benzodiazepines	
Yoshio Japan Prospective 67.7 N/A Bolus midazolam and Esophagu 17.3 (8) N/A
2019 confrmatory (5.7) pethidine + dex s	
single arm infusion;	
Midazolam and	
pethidine boluses	